PTK2 and cancer: Moreover, FAK inhibition by PF-573228 did not show improved anticancer effects in ovarian cancer as opposed to the other cancer types from a drug screening provided by the cancer therapeutics response portal (CTRP) (Supplementary Fig. 1B) [27].